News – Page 1023 – Endpoints News

GSK wins yet another reprieve for blockbuster Advair franchise as Mylan is hit (again) with a CRL

7 years ago

On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression

7 years ago

Blame the ozanimod fiasco on the Receptos team? Just wait a sec, says ex-CEO, who sold the company to Celgene for ...

7 years ago

Buyout buzz bumps Madrigal stock further north, stoking the industry's NASH obsession

7 years ago

This extravagant party during #BIO18 featured topless dancers, and industry leaders are not pleased

7 years ago

UK bank launches £2.5B plan to fund innovation, with a special place for its long-ailing biotech scene

7 years ago

BridgeBio doubles down on rare disease with CoA launch; Beleaguered scPharmaceuticals' shares wilt again on FDA's ...

7 years ago

SF venture fund Alta Partners misses original mark, raising $130M for ninth fund

7 years ago

Eisai is building a bespoke Cambridge research center with a $100M-plus plan to find new ways to tackle Alzheimer's

7 years ago

Flex sends out an SOS signal, scrapping studies and slashing staff as it hunts a survival strategy — shares crater

7 years ago

Top Celgene exec pins the blame for ozanimod fiasco on the Receptos team — acquired 3 years ago

7 years ago

Little vTv Therapeutics adds another round of bad data on Alzheimer's drug, but they still love their chances

7 years ago

Cellectis, rising star Allogene design an 'all-in-one' CAR construct with embedded safety switch as the new partners ...

7 years ago

Stepping into the pricing debate, FDA chief Scott Gottlieb proposes new reimbursement idea for antibiotics

7 years ago

Idera shares slide on PhII failure; WuXi blueprints $60M manufacturing center in Worcester, MA

7 years ago

Prominent cancer biologist Inder Verma resigns from Salk in wake of sexual harassment allegations

7 years ago

Galmed's stock rockets up as execs tout a mixed set of NASH data

7 years ago

GSK’s high-level management makeover continues as CEO Emma Walmsley oversees changing of the guard

7 years ago

Roche CEO Severin Schwan isn’t about to tamper with a winning R&D strategy now, but he’s still looking for ways ...

7 years ago

With a big assist from the FDA, Sage plots a swift march through PhIII for oral depression drug -- market cap swells ...

7 years ago

Novartis hands Regenxbio $100M in fast cash for vector tech

7 years ago

PhIII Alzheimer’s drug goes bust — and a major setback at Eli Lilly and AstraZeneca may doom the class

7 years ago

Gene editing stocks get bushwhacked as new studies highlight CRISPR/Cas9 cancer risks

7 years ago

BridgeBio bags Alexion's ultra-rare disease asset; Allergan touts a new set of late-stage data for oral CGRP drug

7 years ago

First page Previous page 1020 1021 102210231024 1025 1026 Next page Last page